We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$107M
1-Year Est. Return
82.62%
This Fund
S&P 500
This Quarter
Est. Return
-19.3%
1 Year Est. Return
+82.62%
3 Year Est. Return
+219.47%
5 Year Est. Return
+202.9%
10 Year Est. Return
–
AUM
$82.8M
AUM Growth
-$28.8M
(-26%)
Cap. Flow
-$2.79M
Cap. Flow
% of AUM
-3.37%
Top 10 Holdings %
Top 10 Hldgs %
36.35%
Holding
122
New
10
Increased
23
Reduced
52
Closed
15
Top Buys
| 1 |
CareDx
CDNA
|
+$930K |
| 2 |
Gilead Sciences
GILD
|
+$732K |
| 3 |
BEAT
BioTelemetry, Inc.
BEAT
|
+$704K |
| 4 |
Alphatec Holdings
ATEC
|
+$579K |
| 5 |
Rockwell Medical
RMTI
|
+$577K |
Top Sells
| 1 |
Aflac
AFL
|
+$1.02M |
| 2 |
Microvision
MVIS
|
+$808K |
| 3 |
The Joint Corp
JYNT
|
+$802K |
| 4 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$780K |
| 5 |
ANI Pharmaceuticals
ANIP
|
+$709K |
Sector Composition
| 1 | Healthcare | 65.87% |
| 2 | Technology | 10.8% |
| 3 | Communication Services | 7.03% |
| 4 | Industrials | 5.89% |
| 5 | Consumer Staples | 4.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NeoGenomics
NEO
$1.9B
| $6.48M | 7.83% |
234,850
-17,650
| -7% | -$529K |
|
2
Vericel Corp
VCEL
$2.38B
| $3.16M | 3.82% |
344,397
-9,150
| -3% | -$137K |
|
3
Axogen
AXGN
$2.12B
| $3.1M | 3.75% |
298,240
+1,450
| +0.5% | +$18.5K |
|
4
Veracyte
VCYT
$4.72B
| $2.96M | 3.57% |
121,730
-10,900
| -8% | -$274K |
|
5
Idexx Laboratories
IDXX
$44.8B
| $2.71M | 3.28% |
11,205
-145
| -1% | -$37.8K |
|
|
6
CareDx
CDNA
$2.05B
| $2.68M | 3.23% |
122,633
+41,500
| +51% | +$930K |
|
7
Microsoft
MSFT
$2.93T
| $2.57M | 3.11% |
16,318
-67
| -0.4% | -$11K |
|
8
Abbott
ABT
$175B
| $2.23M | 2.69% |
28,243
-50
| -0.2% | -$4.17K |
|
9
Natera
NTRA
$38.9B
| $2.21M | 2.66% |
73,850
-8,050
| -10% | -$269K |
|
|
CSII
10
DELISTED
Cardiovascular Systems, Inc.
CSII
| $1.99M | 2.4% |
56,433
-2,350
| -4% | -$99.1K |
|
|
11
Rockwell Medical
RMTI
$24.2M
| $1.98M | 2.39% |
8,781
+2,023
| +30% | +$577K |
|
12
Eli Lilly
LLY
$1.05T
| $1.95M | 2.36% |
14,058
-42
| -0.3% | -$5.77K |
|
13
AtriCure
ATRC
$1.77B
| $1.71M | 2.06% |
50,750
+2,050
| +4% | +$73.7K |
|
14
Pfizer
PFE
$143B
| $1.71M | 2.06% |
55,069
+113
| +0.2% | +$3.85K |
|
15
LeMaitre Vascular
LMAT
$2.32B
| $1.61M | 1.94% |
64,530
+2,500
| +4% | +$77.2K |
|
16
Magnite
MGNI
$2.72B
| $1.58M | 1.91% |
284,283
-21,450
| -7% | -$197K |
|
|
FPAY
17
DELISTED
FlexShopper
FPAY
| $1.57M | 1.89% |
1,234,950
+102,550
| +9% | +$232K |
|
18
CryoPort
CYRX
$832M
| $1.56M | 1.89% |
91,600
-7,500
| -8% | -$131K |
|
19
OptimizeRx
OPRX
$126M
| $1.53M | 1.85% |
168,670
-3,502
| -2% | -$33.2K |
|
|
BEAT
20
DELISTED
BioTelemetry, Inc.
BEAT
| $1.49M | 1.8% |
38,735
+15,285
| +65% | +$704K |
|
21
Exagen
XGN
$106M
| $1.33M | 1.61% |
83,650
-2,200
| -3% | -$43.7K |
|
|
ASPU
22
DELISTED
ASPEN GROUP, INC.
ASPU
| $1.32M | 1.6% |
165,500
+10,200
| +7% | +$85.5K |
|
|
IDXG
23
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
| $1.16M | 1.4% |
224,107
-5,482
| -2% | -$39.7K |
|
24
AT&T
T
$152B
| $1.15M | 1.38% |
52,072
-970
| -2% | -$26.5K |
|
|
VG
25
DELISTED
Vonage Holdings Corporation
VG
| $1.13M | 1.36% |
155,550
+60,275
| +63% | +$491K |
|
Similar funds
EWL
ECM
HCA
CWM
SNPAM
TWM
ACL
FMI
Perkins Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Perkins Capital Management held 122 positions worth $82.8M, down 26% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Perkins Capital Management withdrew a net $2.79M in Q1 2020, closing 15 positions and reducing 52 holdings. Its most notable exit was Aflac, an estimated $1.02M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 63% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Perkins Capital Management opened a new position in Gilead Sciences worth $792K.
- Perkins Capital Management's largest Q1 2020 buy was Gilead Sciences: 10,600 shares worth $792K.
- Perkins Capital Management added most to CareDx in Q1 2020, an estimated $930K increase.
- Perkins Capital Management's biggest Q1 2020 reduction was Veritone, cutting an estimated $542K.
- Perkins Capital Management fully exited Aflac in Q1 2020, selling an estimated $1.02M.
- Perkins Capital Management's ten largest holdings make up 36% of its $82.8M portfolio in Q1 2020.
- Perkins Capital Management opened 10 new positions and closed 15 in Q1 2020.
- Perkins Capital Management's portfolio value fell 26% quarter-over-quarter to $82.8M.
Based on Perkins Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.